In addition to all the other membership benefits, MSCO is investing in the future of oncology by supporting the professional development and research of young clinicians and fellows.
The Massachusetts Society of Clinical Oncology (MSCO) is pleased to announce that as part of our efforts to support the growth and future of the oncology profession, we will be providing a grant for oncology professionals from Massachusetts to travel to the ASCO Annual Meeting.
Among the recipients of the MSCO Travel Grant will be one fellow of an ACGME-accredited training program and one young clinician (with less than five years of practice).
The application deadline is April 1st.Download application and submission requirements
Thank you to everyone who applied. 2023 ASCO travel grants were awarded to the following individuals:
We are thrilled that MSCO was able to support you on your journey.
The Massachusetts Society of Clinical Oncologists (MSCO) is proud to annually fund one Young Investigator Award (YIA) for a qualified Massachusetts applicant through Conquer Cancer, the ASCO Foundation. We encourage all eligible Massachusetts Fellows and Trainees to apply. The YIA is a one-year, $57,500 grant that provides research funding to promising physicians to support their transition from final years of subspecialty training to faculty appointment and to encourage and promote quality research in clinical oncology. For questions about eligibility, please contact Conquer Cancer at email@example.com.
Arielle Medford, MD, Massachusetts General Hospital
“MDM2 inhibition for patients with hormone-receptor positive, GATA3-mutant metastatic breast cancer”
Evan Chen, MD, a Physician, Division of Leukemia, Dana-Farber Cancer Institute.
A Phase 1 study of adding navitoclax to the combination of venetoclax and decitabine for advanced myeloid malignancies.
Praful Ravi, MBBChir, MRCP, a Medical Oncologist at the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, is the recipient of the inaugural YIA Award supported by MSCO.
A Phase 2 trial of palbociclib in combination with axitinib and avelumab in metastatic clear cell renal cell carcinoma.